Neuren Pharmaceuticals' (ASX:NEU) partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.
Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.
The application is expected to be approved in the first quarter of 2026, the filing said.
Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.
Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。